ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2221

Recognition of Secondary Fibromyalgia Using an Index of 3 Components of the Multi-Dimensional Health Assessment Questionnaire: 90% Agreement with ACR Criteria for Fibromyalgia

Kathryn Gibson1,2, Isabel Castrejón3, Theodore Pincus3 and Katherine J. Bryant4, 1Liverpool Hospital, Sydney, Sydney, Australia, 2Ingham Research Institute, Liverpool, Australia, 3Rheumatology, Rush University Medical Center, Chicago, IL, 4University of New South Wales, Sydney, Australia

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: classification criteria, fibromyalgia, Osteoarthritis, questionnaires and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Secondary fibromyalgia (FM) is seen 15-20% of patients with rheumatoid arthritis (RA) (1), systemic lupus erythematosus (SLE) (2), osteoarthritis (OA), and other rheumatic diseases. New formal ACR criteria for FM are available (3), but not used in most routine care, largely because it is not feasible for patients with different diagnoses to complete different questionnaires in busy clinical settings. Scores on a Multidimensional Health Assessment Questionnaire/routine assessment of patient index data (MDHAQ /RAPID3) may provide clues to FM (4, 5). We analyzed MDHAQ/RAPID3 scores in patients with RA or OA, who had or did not have secondary FM, to develop a simple index to identify patients with secondary FM comparable to ACR FM Criteria.

Methods: All patients with all diagnoses at one academic center complete an MDHAQ/RAPID3 at all visits before seeing the rheumatologist. Nine MDHAQ measures were studied: 1. a 0-10 physical function (FN) scale; 2. pain (PN) and 3. patient global estimate (PATGL) on 0-10 visual analog scales (VAS) (compiled into a 0-30 RAPID3); 4. sleep quality; 5. anxiety; 6. depression; 7. 0-10 fatigue VAS; 8. 0-48 RADAI self-report of painful joints; 9. 60 item symptom checklist. Patients in this study also completed a widespread pain questionnaire to assess ACR FM Criteria (6), and the rheumatologist assigned a diagnosis of FM independent of any questionnaire results. The 9 MDHAQ measures were analyzed in patients with primary RA or OA for frequencies and area under receiver-operating-characteristic (ROC) curves for secondary FM according to ACR FM Criteria or clinical criteria, to develop a simple FM index for optimal discrimination of secondary FM vs no secondary FM.

Results: 84 patients with OA or RA were studied; 58 did not have secondary FM by ACR criteria or clinical diagnosis, 16 had FM by both criteria, 6 had FM only by clinical criteria, and 4 only by ACR criteria. Agreement between clinical and ACR Criteria was substantial (kappa 0.68, p<0.001) (6), and only data for ACR Criteria are presented. Patients who had secondary FM had higher mean scores on all 9 MDHAQ scales studied and ROC areas>0.80. A simple MDHAQ 0-3 FM index involves allocating one point each for pain≥6/10, RADAI≥16/48, and symptom checklist≥16/60. A score of 2/3 on the MDHAQ FM index classified identically 90% of patients with FM by ACR Criteria.

Conclusion: A simple 0-3 MDHAQ-FM index based on pain, RADAI self-report joint count, and symptom checklist provides 90% agreement with the new ACR FM criteria. The MDHAQ is feasible in busy clinical settings, as the same questionnaire can provide important clinical information in all patients with all diagnoses, and appears useful to identify secondary FM.

Cut-off point, sensitivity, and specificity for MDHAQ item and the composite FM in the Liverpool Hospital Australia dataset (N = 84). FM diagnosis by ACR criteria

 

Cut-off point

ROC Area

Sensitivity

Specificity

Correctly classified

Symptom checklist (0-60)

≥ 16

0.98

77.3%

83.9%

82.1%

RADAI (0-48)

≥ 16

0.90

84.2%

80.8%

81.7%

MDHAQ-PAIN (0-10)

≥ 6

0.88

86.4%

75.8%

78.6%

Composite FM

≥ 1

≥ 2

≥ 3

94.7%

94.7%

63.2%

57.7%

88.5%

96.1%

67.6%

90.1%

87.3%

1. Wolfe et al. Pain. 2011;152:291.

2. Wolfe et al. J Rheumatol. 2009;36:82.

3. Wolfe et al. J Rheumatol. 2011;38;1113.

4. Callahan, Pincus. Arthritis Rheum. 1990;33:1317.

5. DeWalt et al. 2004;22:453.

6. Landis, Koch. Biometrics. 1977;33(1):159-74.


Disclosure: K. Gibson, None; I. Castrejón, None; T. Pincus, Health Report Services Inc., 4; K. J. Bryant, None.

To cite this abstract in AMA style:

Gibson K, Castrejón I, Pincus T, Bryant KJ. Recognition of Secondary Fibromyalgia Using an Index of 3 Components of the Multi-Dimensional Health Assessment Questionnaire: 90% Agreement with ACR Criteria for Fibromyalgia [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/recognition-of-secondary-fibromyalgia-using-an-index-of-3-components-of-the-multi-dimensional-health-assessment-questionnaire-90-agreement-with-acr-criteria-for-fibromyalgia/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/recognition-of-secondary-fibromyalgia-using-an-index-of-3-components-of-the-multi-dimensional-health-assessment-questionnaire-90-agreement-with-acr-criteria-for-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology